Edition:
United States

Endologix Inc (ELGX.OQ)

ELGX.OQ on NASDAQ Stock Exchange Global Select Market

6.80USD
12:47pm EDT
Change (% chg)

$0.16 (+2.41%)
Prev Close
$6.64
Open
$6.67
Day's High
$6.88
Day's Low
$6.65
Volume
68,641
Avg. Vol
488,497
52-wk High
$14.49
52-wk Low
$4.79

ELGX.OQ

Chart for ELGX.OQ

About

Endologix, Inc. is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company's products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular... (more)

Overall

Beta: 0.80
Market Cap(Mil.): $550.62
Shares Outstanding(Mil.): 82.93
Dividend: --
Yield (%): --

Financials

  ELGX.OQ Industry Sector
P/E (TTM): -- 33.98 29.72
EPS (TTM): -1.92 -- --
ROI: -51.99 12.74 13.00
ROE: -143.15 14.80 14.15

BRIEF-Brown Capital reports a 10.58 pct passive stake in Endologix Inc

* Brown Capital Management LLC reports a 10.58 percent passive stake in Endologix Inc as of Feb 28, 2017 Source text:(http://bit.ly/2miclCd) Further company coverage:

Mar 07 2017

BRIEF-Endologix reports Q4 loss per share of $0.30

* Endologix reports results for the fourth quarter and full year 2016

Feb 22 2017

BRIEF-Endologix completes patient enrollment in the Ovation LUCY Study

* Endologix completes patient enrollment in the Ovation LUCY Study Source text for Eikon: Further company coverage:

Feb 14 2017

BRIEF-COLUMBIA WANGER ASSET MANAGEMENT REPORTS 7.6 PCT PASSIVE STAKE IN ENDOLOGIX INC AS OF DEC 31, 2016

* COLUMBIA WANGER ASSET MANAGEMENT LLC REPORTS 7.6 PERCENT PASSIVE STAKE IN ENDOLOGIX INC AS OF DEC 31, 2016 - SEC FILING Source text (http://bit.ly/2kcBtG5) Further company coverage:

Feb 10 2017

BRIEF-Endologix appoints Dan Lemaitre as chairman of board

* Endologix announces appointment of Dan Lemaitre as chairman of the board

Feb 06 2017

BRIEF-ENDOLOGIX SAYS CE MARK FOR AFX AND AFX2 ENDOVASCULAR AAA SYSTEMS HAS BEEN REINSTATED

* RECEIVED NOTICE FROM ITS NOTIFIED BODY IN EUROPEAN UNION THAT CE MARK FOR AFX AND AFX2 ENDOVASCULAR AAA SYSTEMS HAS BEEN REINSTATED

Jan 25 2017

BRIEF-ENDOLOGIX RESUMES SHIPMENTS OF ALL SIZES OF AFX2 ENDOVASCULAR AAA SYSTEMS

* ENDOLOGIX RESUMES SHIPMENTS OF ALL SIZES OF AFX2 ENDOVASCULAR AAA SYSTEMS

Jan 17 2017

BRIEF-Endologix provides update on Nellix PMA process

* Endologix Inc says expects data to be available and submitted to FDA in Q2 of 2017

Nov 16 2016

More From Around the Web

Competitors

Earnings vs. Estimates